Another jam packed edition this week! From a nationwide survey in France revealing that up to 13.4% of the general adult population may suffer from long COVID, depending on the definition used, to groundbreaking research identifying abzymes that could explain the persistent symptoms experienced by some patients. This newsletter will explore the multifaceted nature of long COVID, including its higher prevalence among certain demographic groups and the critical need for a unified definition to advance research and patient care. We'll also highlight innovative approaches to treatment, such as targeting specific antibodies and exploring the efficacy of existing medications for relieving symptoms. And a new project helps people with Long Covid find clinical trials and participate in research.
Interesting! My POTS/dysautonomia seemed to improve with antihistamines- Benadryl, Pepcid and Zyrtec. But ALL my LC symptoms , including the extreme fatigue and PEM, resolved completely after taking the 5 day course of paxlovid !
Interesting! My POTS/dysautonomia seemed to improve with antihistamines- Benadryl, Pepcid and Zyrtec. But ALL my LC symptoms , including the extreme fatigue and PEM, resolved completely after taking the 5 day course of paxlovid !